Hep Email Update
Hepatitis C Drugs Show Promise Against New Coronavirus

Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.

Advertisement
FDA Delays Approval of Ocaliva for Fatty Liver Disease

The regulatory agency requested further data to show whether its benefits outweigh its risks.

Fatty Liver Disease Is Less Common but More Severe in Women

While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.

#Coronavirus
Get the latest updates!
Still a Hero
In honor of Hep commemorating 10 years, we are spotlighting 10 inspiring activists: Lucinda K. Porter, RN, remains passionate about hepatitis C advocacy.
Hep Spring 2020
Read the latest issue!
Advertisement

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@hepmag.com. Please remember to add update@hepmag.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is:

Smart + Strong
212 W 35th St Fl 8
New York, NY 10001-2508

Add us to your address book

Copyright (C) 2020 Smart + Strong 212 W 35th St Fl 8 New York, NY 10001-2508 USA All rights reserved.
Terms Of Use and Your Privacy.